S L Williams - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

S L Williams

Showing results (81-90 of 83) with videos related to

Pageof 9

Sort By:

You have reached the last page of results.This site can display upto 83 results.

Neurogastroenterology and Motility|February 7, 2013

An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trialsJ E Macdougall, J M Johnston, B J Lavins, et al.

The Lancet. Neurology|August 10, 2019

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.

Neurology|February 18, 2021

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.

Pageof 9

Search research articles

Showing results (81-90 of 83) with videos related to

Sort By:

Pageof 9

You have reached the last page of results.This site can display upto 83 results.

Neurogastroenterology and Motility|February 7, 2013

An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trialsJ E Macdougall, J M Johnston, B J Lavins, et al.

The Lancet. Neurology|August 10, 2019

Neurology|February 18, 2021

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.

Pageof 9